57118-89-5

Usage

Heterocyclic compound

1H-Imidazole, 4-(chloromethyl)-2-phenylis a five-membered ring containing three carbon atoms, two nitrogen atoms, and two double bonds.

Chlorinated derivative

This chemical features a chlorine atom attached to the fourth position of the imidazole ring.

Phenyl group

A phenyl group is attached to the second position of the imidazole ring.

Building block in organic synthesis

This chemical is commonly used as a building block in organic synthesis, particularly in the pharmaceutical industry for the production of various drugs and pharmaceutical compounds.

Versatile intermediate

The chloromethyl group allows for further functionalization through reactions with other organic compounds, making it a versatile intermediate for the synthesis of a wide range of chemical products.

Upstream product

• 618-39-3 benzamidin 
• 43002-54-6 5-hydroxymethyl-2-phenyl-1H-imidazole 

Downstream Products

• 702631-29-6 (2-phenyl-3H-imidazol-4-yl)-acetic acid 
• 52353-66-9 2-(2-phenyl-1H-imidazol-5-yl)acetonitrile 
• 178928-68-2 NGD₉₄-1 

Relevant academic research and scientific papers

PYRROLOPYRIMIDINES AS CFTR POTENTIATORS

The present invention relates to compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiator

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)

Bisphosphonates (BPs) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a metabolically stable P-C-P structure. Pamidronate (1b, Novartis), a second-generation BP, was the starting point for extensive SAR studies. Small changes of the structure of pamidronate lead to marked improvements of the inhibition of osteoclastic resorption potency. Alendronate (1c, MSD), with an extra methylene group in the N-alkyl chain, and olpadronate (1h, Gador), the N,N-dimethyl analogue, are about 10 times more potent than pamidronate. Extending one of the N-methyl groups of olpadronate to a pentyl substituent leads to ibandronate (1k, Roche, Boehringer-Mannheim), which is the most potent close analogue of pamidronate. Even slightly better antiresorptive potency is achieved with derivatives having a phenyl group linked via a short aliphatic tether of three to four atoms to nitrogen, the second substituent being preferentially a methyl group (e.g., 4g, 4j, 5d, or 5r). The most potent BPs are found in the series containing a heteroaromatic moiety (with at least one nitrogen atom), which is linked via a single methylene group to the geminal bisphosphonate unit. Zoledronic acid (6i), the most potent derivative, has an ED50 of 0.07 mg/kg in the TPTX in vivo assay after sc administration. It not only shows by far the highest therapeutic ratio when comparing resorption inhibition with undesired inhibition of bone mineralization but also exhibits superior renal tolerability. Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa. The results of the clinical trials indicate that low doses are both efficacious and safe for the treatment of tumor-induced hypercalcemia, Paget's disease of bone, osteolytic metastases, and postmenopausal osteoporosis.

2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding

A series of 2-phenyl-4-(aminomethyl)imidazoles were designed as conformationally restricted analogs of the dopamine D2 selective benzamide antipsychotics.The title compounds were synthesized and tested for blockade of YM-09151 binding in cloned African green monkey dopamine D2 receptor preparations.The binding affinity data thus obtained were compared against that of the benzamides and a previously described series of 2-phenyl-5-(aminomethyl)pyrroles.